Drug Profile
Research programme: central nervous system disorder therapeutics - Effipharma
Latest Information Update: 28 Sep 2020
Price :
$50
*
At a glance
- Originator Effipharma
- Class Antidementias; Antiparkinsonians; Antipsychotics
- Mechanism of Action Dopamine D1 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Alzheimer's disease; Parkinson's disease; Schizophrenia
Most Recent Events
- 28 Sep 2020 No recent reports of development identified for research development in Alzheimer's-disease in USA
- 28 Sep 2020 No recent reports of development identified for research development in Parkinson's-disease in USA
- 28 Sep 2020 No recent reports of development identified for research development in Schizophrenia in USA